8-K filed May 15, 2024, 7:59 PM ET CIK 0001840904

leadership confidence high sentiment neutral materiality 0.80

CEO Florian Brand to step down by YE2024; Dr. Rao to succeed; Q1 net loss $26.7M

ATAI Life Sciences N.V.

CEO Florian Brand to step down by Dec 31, 2024; will serve as Co-CEO from June 1 until then.
Co-Founder Dr. Srinivas Rao appointed Co-CEO effective June 1, 2024; to become CEO by YE2024.
Q1 2024 net loss $26.7M ($33.1M in Q1 2023); R&D expenses $11.5M, down from $19.3M YoY.
Cash, equivalents and short-term investments $121.3M at March 31, 2024; sufficient into 2026.
VLS-01 Phase 1b data and BPL-003 Phase 2b TRD topline data both expected in 2H 2024.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Srinivas Rao

Co-Chief Executive Officer

ATAI Life Sciences N.V.

Effective: 2024-06-01
Filed: May 15, 2024, 7:59 PM ET

Effective June 1, 2024, Dr. Srinivas Rao was appointed the Company's Co-Chief Executive Officer and designated as co-principal executive officer.

Role change

Florian Brand

Co-Chief Executive Officer

ATAI Life Sciences N.V.

Effective: 2024-06-01
Filed: May 15, 2024, 7:59 PM ET

Mr. Brand will serve as Co-Chief Executive Officer of the Company from June 1, 2024 through December 31, 2024

Departed

Florian Brand

Chief Executive Officer

ATAI Life Sciences N.V.

Effective: 2024-12-31
Successor: Srinivas Rao
Filed: May 15, 2024, 7:59 PM ET

at which time he will be stepping down from his position as the Company's Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ATAI Life Sciences N.V. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 15, 2024, ATAI Life Sciences N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Srinivas Rao was appointed as Co-Chief Executive Officer at ATAI Life Sciences N.V..

Action: appointed
Role: Co-Chief Executive Officer

Exact text from the filing

Effective June 1, 2024, Dr. Srinivas Rao was appointed the Company's Co-Chief Executive Officer and designated as co-principal executive officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Florian Brand changed role as Co-Chief Executive Officer at ATAI Life Sciences N.V..

Role: Co-Chief Executive Officer

Exact text from the filing

Mr. Brand will serve as Co-Chief Executive Officer of the Company from June 1, 2024 through December 31, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Florian Brand departed as Chief Executive Officer at ATAI Life Sciences N.V..

Action: stepping down
Role: Chief Executive Officer

Exact text from the filing

at which time he will be stepping down from his position as the Company's Chief Executive Officer

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001140361-24-026094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.